Inhibition of tumor growth by the intralesional administration of interleukin-3 into mice implanted with solid tumors

H. Sasaki, D. A. Schmitt, Y. Hayashi, R. B. Pollard, Fujio Suzuki

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The anitumor activity of three interleukin-3 (IL-3) preparations administered intralesionally into mice bearing syngeneic solid tumors was investigated. IL-3 preparations used in this study included S-IL-3, which was isolated from the culture fluid of murine inguinal lymph node cells stimulated with an arabinomannan extracted from Mycobacterium tuberculosis (SSM), the culture fluid of WEHI-3 cells (W-IL-3) and recombinant IL-3 (rIL-3). When a 1,500 U/kg dose of S-IL-3 or W-IL-3 was injected intralesionally into BALB/c mice bearing Meth-A solid tumors three time per week beginning 3 days after tumor inoculation, tumor growth was inhibited by 60% or 74% at 24 days after tumor inoculation, respectively. In these experiments, 1 unit of IL-3 activity was determined to be the concentration that induced 50% of maximal proliferation of an IL-3 dependent cell line (FCD-P2 cells). The administration of this dose of rIL-3 inhibited tumorgrowth by 34%. When these three preparations of IL-3 were pretreated with anti-lL-3 monoclonal antibody in vitro, the antitumor activity, as well as their growth promoting activity on FDC-P2 cells, was eliminated. Since direct cytotoxic activities of these IL-3 preparations against cultured Meth-A tumor cells in vitro have not been demonstrated, these results suggest that their antitumor activities might be expressed through interactions between tumor cells and antitumor effector cells which were stimulated by the intralesional administration of the IL-3 preparations.

Original languageEnglish (US)
Pages (from-to)313-315
Number of pages3
JournalAnticancer Research
Volume12
Issue number2
StatePublished - 1992

Fingerprint

Interleukin-3
Growth
Neoplasms
Groin
Mycobacterium tuberculosis
Lymph Nodes

Keywords

  • Antitumor activity
  • Interleukin-3
  • Solid tumors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Inhibition of tumor growth by the intralesional administration of interleukin-3 into mice implanted with solid tumors. / Sasaki, H.; Schmitt, D. A.; Hayashi, Y.; Pollard, R. B.; Suzuki, Fujio.

In: Anticancer Research, Vol. 12, No. 2, 1992, p. 313-315.

Research output: Contribution to journalArticle

Sasaki, H. ; Schmitt, D. A. ; Hayashi, Y. ; Pollard, R. B. ; Suzuki, Fujio. / Inhibition of tumor growth by the intralesional administration of interleukin-3 into mice implanted with solid tumors. In: Anticancer Research. 1992 ; Vol. 12, No. 2. pp. 313-315.
@article{78af430d73b04ad1a637af00903d3d77,
title = "Inhibition of tumor growth by the intralesional administration of interleukin-3 into mice implanted with solid tumors",
abstract = "The anitumor activity of three interleukin-3 (IL-3) preparations administered intralesionally into mice bearing syngeneic solid tumors was investigated. IL-3 preparations used in this study included S-IL-3, which was isolated from the culture fluid of murine inguinal lymph node cells stimulated with an arabinomannan extracted from Mycobacterium tuberculosis (SSM), the culture fluid of WEHI-3 cells (W-IL-3) and recombinant IL-3 (rIL-3). When a 1,500 U/kg dose of S-IL-3 or W-IL-3 was injected intralesionally into BALB/c mice bearing Meth-A solid tumors three time per week beginning 3 days after tumor inoculation, tumor growth was inhibited by 60{\%} or 74{\%} at 24 days after tumor inoculation, respectively. In these experiments, 1 unit of IL-3 activity was determined to be the concentration that induced 50{\%} of maximal proliferation of an IL-3 dependent cell line (FCD-P2 cells). The administration of this dose of rIL-3 inhibited tumorgrowth by 34{\%}. When these three preparations of IL-3 were pretreated with anti-lL-3 monoclonal antibody in vitro, the antitumor activity, as well as their growth promoting activity on FDC-P2 cells, was eliminated. Since direct cytotoxic activities of these IL-3 preparations against cultured Meth-A tumor cells in vitro have not been demonstrated, these results suggest that their antitumor activities might be expressed through interactions between tumor cells and antitumor effector cells which were stimulated by the intralesional administration of the IL-3 preparations.",
keywords = "Antitumor activity, Interleukin-3, Solid tumors",
author = "H. Sasaki and Schmitt, {D. A.} and Y. Hayashi and Pollard, {R. B.} and Fujio Suzuki",
year = "1992",
language = "English (US)",
volume = "12",
pages = "313--315",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - Inhibition of tumor growth by the intralesional administration of interleukin-3 into mice implanted with solid tumors

AU - Sasaki, H.

AU - Schmitt, D. A.

AU - Hayashi, Y.

AU - Pollard, R. B.

AU - Suzuki, Fujio

PY - 1992

Y1 - 1992

N2 - The anitumor activity of three interleukin-3 (IL-3) preparations administered intralesionally into mice bearing syngeneic solid tumors was investigated. IL-3 preparations used in this study included S-IL-3, which was isolated from the culture fluid of murine inguinal lymph node cells stimulated with an arabinomannan extracted from Mycobacterium tuberculosis (SSM), the culture fluid of WEHI-3 cells (W-IL-3) and recombinant IL-3 (rIL-3). When a 1,500 U/kg dose of S-IL-3 or W-IL-3 was injected intralesionally into BALB/c mice bearing Meth-A solid tumors three time per week beginning 3 days after tumor inoculation, tumor growth was inhibited by 60% or 74% at 24 days after tumor inoculation, respectively. In these experiments, 1 unit of IL-3 activity was determined to be the concentration that induced 50% of maximal proliferation of an IL-3 dependent cell line (FCD-P2 cells). The administration of this dose of rIL-3 inhibited tumorgrowth by 34%. When these three preparations of IL-3 were pretreated with anti-lL-3 monoclonal antibody in vitro, the antitumor activity, as well as their growth promoting activity on FDC-P2 cells, was eliminated. Since direct cytotoxic activities of these IL-3 preparations against cultured Meth-A tumor cells in vitro have not been demonstrated, these results suggest that their antitumor activities might be expressed through interactions between tumor cells and antitumor effector cells which were stimulated by the intralesional administration of the IL-3 preparations.

AB - The anitumor activity of three interleukin-3 (IL-3) preparations administered intralesionally into mice bearing syngeneic solid tumors was investigated. IL-3 preparations used in this study included S-IL-3, which was isolated from the culture fluid of murine inguinal lymph node cells stimulated with an arabinomannan extracted from Mycobacterium tuberculosis (SSM), the culture fluid of WEHI-3 cells (W-IL-3) and recombinant IL-3 (rIL-3). When a 1,500 U/kg dose of S-IL-3 or W-IL-3 was injected intralesionally into BALB/c mice bearing Meth-A solid tumors three time per week beginning 3 days after tumor inoculation, tumor growth was inhibited by 60% or 74% at 24 days after tumor inoculation, respectively. In these experiments, 1 unit of IL-3 activity was determined to be the concentration that induced 50% of maximal proliferation of an IL-3 dependent cell line (FCD-P2 cells). The administration of this dose of rIL-3 inhibited tumorgrowth by 34%. When these three preparations of IL-3 were pretreated with anti-lL-3 monoclonal antibody in vitro, the antitumor activity, as well as their growth promoting activity on FDC-P2 cells, was eliminated. Since direct cytotoxic activities of these IL-3 preparations against cultured Meth-A tumor cells in vitro have not been demonstrated, these results suggest that their antitumor activities might be expressed through interactions between tumor cells and antitumor effector cells which were stimulated by the intralesional administration of the IL-3 preparations.

KW - Antitumor activity

KW - Interleukin-3

KW - Solid tumors

UR - http://www.scopus.com/inward/record.url?scp=0026604227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026604227&partnerID=8YFLogxK

M3 - Article

C2 - 1580549

AN - SCOPUS:0026604227

VL - 12

SP - 313

EP - 315

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -